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MAY, Sheldon W. 
A. SPECIFIC AIMS 
To date, we have developed several classes of compounds which we have shown to be either: (a) novel, 
potent substrate analogs for dopamine beta-monooxygenase (DBM) capable of competing with dopamine 
for enzymatic oxygenation; (b) substrates which cause a DBM-turnover-dependent local ascorbate 
depletion cycle to occur; (c) mechanism-based irreversible inhibitors or reversible inhibitors ofDBM. For 
several of our compounds we have demonstrated a potent antihypertensive activity, and we hypothesize 
that this activity arises via a modulation of adrenergic neuronal activity mediated through DBM 
oxygenation. The broad objectives of our program are to conf1I1Il key aspects of the biochemical and 
pharmacological mechanism responsible for the antihypertensive activity of compounds in hand, and to 
extend our efforts by continuing the design, synthesis, and evaluation of other novel compounds 
potentially capable of modulation of adrenergic neuronal activity. 
Selenium-Containine Compounds; The unique aspect of this class of compounds arises from our 
hypothesis that they cause modulation of adrenergic neuronal activity through the novel strategy of · 
turnover-dependent local depletion of the essential DBM cofactor, reduced ascorbate (ASCH2 )· Because 
of this unique mechanism, these compounds may have wide ranging applications in neuroscience - in 
addition to their potential as hypotensive agents - so it is critical that we confinn our hypothesized 
mechanism of action. We will demonstrate this process directly in cell culture, show correlation between 
the enantioselectivities of enzymatic turnover and ASCH2 depletion even in the presence of fully · 
functional b561 recycling system, probe whether we can "fine tune" turnover-dependent recycling - in a 
kinetic sense -by judicious choice of the particular selenide substrate, and determine effective tissue 
concentrations for correlation with isolated tissue experiments. 
Sulfur-Containine Compounds: This class represents our simplest strategic approach to the 
modulation of adrenergic neuronal activity. We will demonstrate that the key elements of the mechanism 
are operative in functioning cells in culture, carry out pharmacodynamics to conf1I1I1 a primarily peripheral 
locus of action and minimal CNS access for hydroxylated derivatives (a key consideration in any eventual 
clinical utilization of hydroxy derivatives of many of our various classes of compounds), and correlate the 
enantioselectivity of DBM sulfoxidation and effects in PC-12 cell culture and granule ghosts. 
Optimized Suicide Substrates: We will draw one our extensive kinetic and mechanistic 
enzymological characterization of our "olefmic" and "N-dealkylation" mechanism-based inhibitors wherein 
we have developed compounds which are rapid inactivators with very low partition ratios (as low as unity) 
but still maintain structural features necessary for solubility and presynaptic uptake. Thorough bioassays 
in SHR as well as companion experiments to demonstrate cellular and subcellular uptake, enzymatic 
oxygenation, and effects on adrenergic outflow will be carried out. 
New DBM-Iar&eted Compounds: Five new classes of DBM-targeted compounds, which we 
reason will be potent suicide substrates, prodrugs, pseudosubstrates or high affmity non-covalent 
inhibitors, will be synthesized and fully characterized as to enzymology. Those compounds whose 
structural features, chemical properties and enzymological parameters are most promising will be 
bioassayed in SHR and examined at the cellular and subcellular levels. 
Tyrosine Hydroxylase CTH); We will carry out a very limited pilot evaluation of one class of 
compounds targeted at the enzyme TH, in order to provide a measure of the importance of the sequestering 
and uptake accessibility of DBM in terms of rationale drug design. Also, if 1H is indeed the rate limiting 
step in the NE biosynthesis pathway, we may obtain insight into the consequencesof ''DBM-targeted 
modulation" vs more drastic "Til-targeted cutoff' on NE production. The specificity demands of 1H for 
an amino acid structure will limit these experiments to the enzyme and cellular levels, and no bioassays in 
SHR are planned. 
DBM Mechanism; We will continue our contributions to the mechanistic enzymology of DBM by 
demonstrating DBM-catalyzed aromatization of compounds designed to trap reaction transients generated 
by single electron transfer and through active site peptide mapping with one of our suicide inhibitors which 
is ideal for this purpose. 
• BACKGROUND AND SIGNIFICANCE 
Cardiovascular diseases are the leading cause of premature mortality in industrialized nations. 
Hypertension of unknown etiology may be the major causative factor in the genesis of these diseases (1). 
Traditionally, hypertension has been treated clinically by employing agents which either: (a) are 
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antagonists at various classes of adrenergic receptors; (b) modify renal function (to induce diuresis, for 
example); (c) act directly on smooth muscle (vasodilators); (d) act as neuronal blockers (reserpine, 
guanethidine); (e) block calcium channels in vascular musculature; or (f) induce alterations in the renin-
angiotensin system (captopril, saralasin, and the like). In recent years, research has been focused in the 
main on the newest of these approaches (calcium blockers, renin-angiotensin inhibitors) while 
considerable progress has been made in the design and testing of adrenergic receptor ligands which are 
more specific for particular receptor sub-populations or discrete anatomical regions (for example, centrally-
active agents such as clonidine or propranolol). A more complete discussion of the treatment of 
hypertension may be found in several very good reviews (2,3). 
We have visualized a possible new approach to the control of hypertension which focuses on an 
important enzyme of catecholamine synthesis: dopamine beta-monooxygenase (EC 1.14.2.1, DBM). 
DBM is a copper-containing enzyme which catalyzes the terminal oxygenation in the synthesis of the 
principal adrenergic neurotransmitter, norepinephrine (NE). It has long been recognized that the 
sympathetic nervous system, and its· neurotransmitter NE, are responsible for regulation of vascular tone 
and the physiology of hypertension (4). Together with data correlating increased NE levels with increased 
blood pressure (5) and with the occUITence of congestive heart failure (6), these facts support a rationale 
for developing compounds which can interfere with NE biosynthesis as potential agents for the treatment 
of hypertension and congestive heart failure. 
In considering such an approach, we immediately recognized two significant advantages of 
focusing on DBM as our target enzyme. First, DBM is an enzyme which is physiologically functional 
only within adrenergic neurotransmitter storage vesicles (and their adrenal homologues, the chromaffm 
granules). This sequestration of DBM away from the nonnal cytosolic flux, and its intil;nate 
compartmentalization with its substrate, product and requisite cofactors, places it in a metabolically 
convenient position for chemical and pharmacological manipulation (e.g., with our selenides which deplete 
local reduced ascorbate; see below). Second, and perhaps most significantly, it is well known that 
termination of adrenergic "fning" is accomplished by the presynaptic reuptake ofNE (and its at least partial 
re-storage in vesicles). This provides a pathway by which our novel chemical agents could gain access to 
- and modify the activity of- DBM, so long as we took care to design compounds possessing those 
structural features essential for presynaptic reuptake. We considered this latter point highly attractive, 
since a major concern in enzyme-targeted drug design is always "How does one target one's novel 
compounds for the enzyme of interest'?" 
There are additional considerations relevant to the rationale of our approach of designing molecules 
targeted at DBM as potential cardiovascular agents. There are four steps in the pathway leading from the 
essential amino acid, Phe, to the neurotransmitter, NE. [Of these, the tyrosine hydroxylase (1H)-
catalyzed hydroxylation of tyrosine to dihydroxyphenylalanine was regarded as the putative rate limiting 
step in the early literature (7), although, as pointed out later (8), there may be a shift toward rate 
detennining DA hydroxylation under certain metabolic conditions.] In any case, since DBM is an "internal 
enzyme" in the catecholamine cascade, an approach aimed at interfering with DBM activity may offer the 
advantage of a diminished probability for enzymatic "upregulation" - with its attendant tachyphylaxis -
upon chronic administration of the drug (9). A second point is that interfering with DBM may lead to a 
buildup of DA, a molecule known to have vasodilator action, particularly in the renal and mesenteric 
vasculature. This is an area in which our collaborator, Professor Leon Goldberg, is an acknowledged 
international authority (see Collaborative Arrangements). Finally, it should be mentioned that if, indeed, 
TH and not DBM is rate determining step in catecholamine biosynthesis, then interfering with DBM may 
cause modulation, rather than virtual shutdown, of adrenergic outflow. This would be of particular 
interest to us since it has been long presumed that many of the side effects of classical receptor antagonists 
is due to their completely "turning off' adrenergic outflow, as opposed to such a more gentle modulation. 
During the course of this project we have elaborated several novel classes of DBM-targeted 
compounds, the oxygenation of many of which represented a heretofore unrecognized activity for DBM. 
Accordingly, in each case, we fli'St had to unequivocally demonstrated that prototypes of each class are 
indeed substrates and/or turnover-dependent inhibitors of DBM. While our ultimate goal is obviously to 
produce compounds with attractive pharmacological properties, our approach has been to fll'St carefully 
defme the enzymology of thes·e compounds and the biochemmtry of their interaction with DBM. 
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Correspondingly, we have carried out bioassays to demonstrate cardiovascular activity of our compounds, 
and a variety of experiments at the tissue, cellular, and subcellular level to establish a link between the 
enzymology of our compounds as DBM substrates and/or inhibitors and a modification of sympathetic 
tone leading to antihypertensive activity. By way of background, the following examples illustrate the 
approaches we have followed in the design of DBM-targeted compounds (Background details can be 
foun~ in references 10-16). 
Our initial goal was to examine the reactivity of DBM toward functionalities other than benzylic C-
H bonds; prior to our work, DBM had been viewed as an absolutely "specific hydtoxylase". In the fll'St 
demonstration of an alternative oxygenation competence by any of the so-called "specific hydroxy lases", 
we reported that DBM oxygenates phenyl2-aminoethyl sulfide (P AES) to the corresponding sulfoxide, 
phenyl2-aminoethyl sulfoxide (PAESO). We examined a number of derivatives ofPAES, and . 
demonstrated that both the parent compound and its ring substituted and/or alpha-methylated derivatives 
are excellent substrates for DBM and are oxygenated to the coiTeSponding sulfoxides via the "normaJ" 
reductive oxygenation pathway of the enzyme. Sulfoxidation of our sulfide substrates is kinetically facile, 
proceeding more rapidly than methylene hydroxylation in cognate substrates. Moreover, sulfoxidation is 
highly stereospecific, exhibiting the same reaction stereochemistry as the nonnal hydroxylation reaction. 
We found that our sulfide substrates exhibit potent antihypertensive ~tivity in SHR. Both chronic 
and acute studies have been canied out at various dose levels, using both direct and indirect blood pressure 
measuring techniques as well as various modes of drug administration. Based on our results we 
suggested a mechanism whereby the sulfides gain access to intravesicular DBM and are enzymatically 
sulfoxidated, thus competing with enzymatic oxygenation of DA toNE. Since we have observed that the 
sulfoxide products are receptor-inactive, the net result is dilution of the NE released at adrenergic nerve 
terminii with a resultant diminution in sympathetic outflow. Our ongoing research activities are directed at 
further elucidation of the mechanism of antihypertensive activity of our sulfides. In addition, refined 
derivatives of P AES with increased potency, enhanced duration of action, and greater peripheral vs central 
selectivity are being prepared and evaluated. 
We next reported the first example of olefmic oxygenation by DBM and demonstrated that this 
process leads to suicide inhibition by 1-phenyl-1-aminomethylethene (PAME). On the basis of kinetics, 
stoichiometry, product trapping, activator effects, and pH dependencies, we established a mechanism-
based mode of inhibition. Reaction of DBM with 3H-P AME resulted in non-dialyzable incorporation of 
radiolabel into the enzyme. Thus, it was clear that olefm oxygenation represented a novel approach to 
suicide inhibition DBM, which might lead to compounds of pharmacological interest. Subsequently, we 
canied out extensive mechanistic studies with derivatives ofPAME, demonstrated that the mechanism of 
olefm oxygenation involves initial generation of an olefin-radical-cation and it is this species and not the · 
ultimate epoxide product which leads to inactivation. We also synthesized andenzymologically 
characterized a number of derivatives of P AME, among them p-OH P AME the most potent suicide 
substrate for DBM theretofore reported, as well as other derivatives with partition ratios especially 
favorable for phannacological purposes. In related work, we also discovered that acetylenic compounds 
(e.g. 1-phenylpropargylamine) are also highly potent suicide substrates for DBM. 
Among the other classes of novel DBM-directed compounds we have developed are product 
enantiomers which are oxidatively ketonized by DBM, and compounds which undergo enzymatic 
dealkylation. In the fll'St case, we have demonstrated that S-enantiomers of the alcohol prOducts nonnally 
formed by DBM (e.g. S-NE; S-octopamine) are readily hydroxylated by DBM to produce gem-diols as the 
immediate enzymatic products, which exist in solution as the corresponding ketones. Since such S-
enantiomers have weak adrenergic activity, while ketone analogs of norepinephrine and epinephrine 
exhibit a number of potent phannacological effects, the ketonization activity ofDBM may be exploitable 
for activation of appropriately designed pro-drugs. In fact, we published the suggestion that this 
ketonization activity is relevant to the bioactivation of norpseudoephedrine and its cognates. In the second 
case, we discovered that DBM readily carries out N-dealkylation of N-phenyl ethylenediamine (PEDA) 
and its cognates in an oxygenative reaction which is kinetically comparable to the other oxygenative 
activities of this enzyme. As detailed in PROGRESS REPoRT, during this current project period we have 
extensively investigated the mechanism of this new N-delakylation activity of DB~J, shown that potent, 
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kinetically well-behaved suicide inactivation occurs concomitant with N-dealkylation, and proposed a 
unified mechanism for oxygenation of heterooatom and olefmic substrates. 
Finally, we designed phenyl-2-aminoethyl selenide (PAESe) as the prototype for a novel class of 
aminoalkyl phenyl selenide DBM substrates. We anticipated that DBM would carry out selenoxidation 
with high facility, but recognized that the expected selenoxide products should exhibit unique reactivity 
and redox properties. We confmned that P AESe is indeed an excellent substrate for DBM and that 
enzymatic oxygenation produces phenyl-2-aminoethyl selenoxide (PAESeO), with kinetic parameters 
comparable to those for oxygenation of other facile substrates. 
What is remarkable about the processing of P AESe by DBM is that the enzymatic product, 
P AESeO, possesses a redox capability unlike that of any other DBM product We observed that under 
standard in vitro assay conditions, P AESeO is non-enzymatically reduced back to P AESe with the 
concomitant and stoichiometric oxidation of reduced ascorbate (ASCH2). This non-enzymatic recycling 
reaction is a facile, stoichiometric process which we thoroughly characterized in our laboratory during this 
current project period. As detailed in PROGRESS REPORT, we have clearly shown in in-vitro experiments 
that once enzymatic processing of P AESe by DBM begins, newly fonned P AESeO is recycled back to 
P AESe, and this cyclic oxidation/reduction pathway continues until reduced ascorbate is depleted. Since 
reduced ascorbate is an essential cofactor for DBM, this in-situ depletion of reduced ascorbate prematurely 
terminates enzymatic activity. These fmdings establish novel biochemistry for the selenide substrate. 
Initial examinations of the effects of P AESe on systemic blood pressure in vivo were equally 
striking. We observed that P AESe exhibits a marked antihypertensive effect in SHR, with as much as a 
SO% reduction in blood pressure. In view of these promising results, it has become a high priority to us to 
focus on the question of whether the antihypertensive activity we observe for our selenides in SHR indeed 
arises via the DBM-dependent ascorbate-depletion process so evident in our in vitro experiments. 
Moreover, it is well documented that catecholamine granules, the physiological locus of DBM catalysis, 
possess a cytochrome b561-dependent ASCH2 recycling system, and it was thus critical for us to 
demonstrate that the selenide-tumover-dependent ASCH2 depletion indeed occurs even in the presence of 
this physiological ASCH2 recycling system. 
C. PROGRESS REPORT 
This project was competitively reviewed by the Bio-Organic & Natural Products Chemistry Study 
Section (Propsal submitted Oct, 1984) and funded for the period 7/1/85-6130/89. 
PUBLICATIONS SINCE LAST COMPETITIVE REYIEW . 
1. "Facile Steroselective Allylic Hydroxylation by Dopamine-beta-Monooxygenase" ~ S.R. Sirimanne and S.W. May, 
J.Am.Chem.Soc-.110, accepted, in press (issue of 26 October) (1988). 
2. "Effects of Dopamine b-Monooxygenase Substrate Analogs on Ascorbate Levels and Noreinephrine Synthesis in 
Adrenal Chromafrm Granule Ghosts", K. Wimalasena, H.H. Herman, and S.W. May, J. Biolog. Chern., accepted, in press 
(1989). . 
3. "Demonstration of the Antihypertensive Activity of Phenyl-2-Aminoethyl Selenide", S. H. Pollock, H. H. Herman, 
L. C. Fowler, A. S. Edwards, C. Evans, and S. W. May, I. Phann. Exp. Therap., 246, 227-234 (1988). 
4. "An Investigation of the Adrenergic Uptake Specificity of Phenyl-2-Aminoethyl Sulfides", .S. H. Pollock, H. H. 
Herman and S. W. May, Arch. Intemat. Phannacodyn. Therap., accepted, in press {1988). 
S. "Novel Antihypertensives Targeted at Dopamine-b-Monooxygenase: Turnover-Dependent Cofactor Depletion by 
Phenyl Aminoethyl Selenide. ",S. W. May, K. Wimalasena, H. H. Herman, L. C. Fowler, M. C. Ciccarello, and S. H. 
Pollock, J. Med Chern., 31, 1066-1068 {1988). 
6. "Demonstration of the Potent AntihypertenSive Activity of Phenyl-2-aminoethyl Sulfides," H. H. Herman, S. H. 
Pollock, L. C. Fowler and S. W. May, J. Cardiovasc. Phannacol., 11, S01-510 (1988). 
7. "Demonstration of the Ascorbate Dependence of Membrane-Bound Dopamine Beta-Monooxygenases in Adrenal 
Chromaffin Granule Ghosts", H. H. Herman, K. Wirnalasena, L. C. Fowler and S. W. May, J. Biolog. Chern., 263, 666-
672 {1988). 
8. "Ascorbate Depletion as a Consequence of Product Recycling During Dopamine-B-Monooxygenase Catalyzed 
Selenoxidation," S. W. May, H. H. Herman, S. R. Roberts, and M. J. Ciccarello, Biochemistty, 26, 1626- 1633 {1987). 
9. "Mechanistic Studies on Dopamine-B-Monooxygenase Catalysis: N-Dealkylation and Mechanism-Based Inhibition 
by Benzylic Nitrogen-Containing Compounds. Evidence for a Single Electron Transfer Mechanism," K. W. Wirnalasena and 
S. W. May, J. Amer. Chern Soc., 109, 4036- 4046 (1987) . ~ 
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10. "Interaction ofDopamine-B-Monooxygenase with Substituted Irnidazoles and Pyrazoles: Catalysis and Inhibition," 
S. R. Sirirnanne, H. Herman, and S. W. May, Biochemical Journal, 242, 227-233 (1987). 
11. "Olefin Oxygenation and N-Dealkylation by Dopamine-B-Monooxygenase: Catalysis and Mechanism-Based 
Inhibition," S. R. Padgette, K. Wimalasena, H.H. Herman, S.R. Sirimanne and S. W. May, Biochemistry, 24, 5826-5839 
(1985). 
12. "Novel Substrates and Inhibitors for Dopamine B-Monooxygenase: Biochemical and Pharmacological Studies," 
S.W. May, H.H. Herman, S.R. Padgette, S.F. Roberts and K. Wimalasena, Acta Phannaceutica Svecica, Suppl., 1985:2, 
302-313 (1985) 
13. "N-Succimidyl Methoxy Phenylacetic Acid Ester, an Amine-Directed Chiral Derivatizing Reagent Suitable for 
Enzymatic Scale Resolutions", P.A. Husain, J.E. Colbert, S.R. Sirimanne, D.O. VanDerveer, H.H. Herman and S.W. May, 
Analyt. Biochem., submitted. 
The Followin& are Published Abstracts 0985-88) 
"Novel Antihypertensives Targeted at Dopamine-b-hydroxylase", Abstracts Third Chemical Congress N. America, 
Toronto ( 1988) . 
"Asymmetric Allylic Oxygenation of2-(1-Cyclohexenyl)Ethylamine by Dopamine-b-Monooxygenase", FASEB J. 
47, 578 (1988). 
"Novel Antihypertensives Targ~ted atDopamine-b-Monooxygenase", FASEB J. 47, 1752 (1988). 
"Comparison of the Antihypertensive Activity of Substrate Analogs for Dopamine Beta-Monooxygenase", S.H. 
Pollock, H.H. Herman, L.C. Fowler, L.M. DeCarlo, and S.W. May, Abstracts Third Annual Symposium on Cardiovascular 
Research, American Heart Association, Georgia Affiliate, (1988). 
"Determination of the Anorectic Activity of Substrate Analogs for Dopamine Beta-Monooxygenase", J.M. 
Holbrook, S.W. May, H.H. Herman, S.H. Pollock, D. Jones, W.B. Rose, and M. Shelton, Abstracts Third Annual 
Symposium on Cardiovascular Research, American Heart Association, Georgia Affiliate, (1988). 
"Antihypertensive Activity and Ascorbate Depletion via Product recycling by DBM-Targeted Selenides", Fed Proc. 
46, 1940 (1987). -
(1987). 
"Mechanistic and Specificity Studies on Dopamine Beta Monooxygenase Catalysis", Fed. Proc. 46,2043 (1987). 
"The Antihypertensive Activity of a Selenium-Containing Analog of Phenylpropylamine", Fed. Proc. 46,. 1290 
"New Catalytic Activities for a Prototypical Non-Heme Iron Monooxygenase", Fed. Proc. 45, 1537 (1986) 
"The Antihypertensive Activity of a Selenium-Containing Analog of Phenylpropylamine", S.H. Pollock, H.H. 
Herman, S.W. May, L.C. Fowler, and A.S. Edwards, Abstracts First Annual Symposium on Cardiovascular Research, 
American Heart Association, Georgia Affiliate, (1986). 
"Mechanistic Studies on Dopamine-b-Monooxygenase Catalysis: N-Dealkylation and Mechanism-Based Inhibition. 
Evidence for a Single Electron Transfer Mechanism", Fed.Proc. 45, 1537 (1986) 
"Dopamine-b-Hydroxylase: New Catalytic Activities and Mechanism-Based Inhibition", Fed. Proc. 44, 1054 (1985) 
"Anti-Hypertensive Activity of Novel DBM Substrates" Fed. Proc. 44, 879 (1985). 
Personnel 
Faculty: Sheldon W. May, Professor of Chemistry (PI) and Heath H. Herman, Research Scientist since start of project. 
Technjcians· L. Fowler, 2 years; F. Young, 1 year 
Postdoctpra} Assgciates: K. W. Wimalasena; A.K. Katopodis 
Graduate Stydents: K. Wimalasena, S, Sirimanne, P. Husain, L. Fowler 
Our objectives for tbjs period were: 
To thoroughly characterize the pharmacology and antihypertensive activity we had preliminarily 
observed with compounds from two different classes of DBM substrate analogs (the sulfur-containing and 
selenium-containing classes) and initiate bioassay of derivatives of additional classes of our DBM substrate 
analogs (the olefinic class and the N-dealkylating class); 
To explore the subcellular mechanism of action of selected compounds by first demonstrating 
vesicular and cellular uptake and then enzymatic conversion, of our compounds along with a 
characterization of the attendant biochemical mechanism of action at the subcellular level; · 
To extend our efforts to other novel classes of compounds. 
Substantial progress has been made in all of these areas. We have thoroughly investigated the 
phannacology and antihypertensive activity of our two most-studied classes of compounds and have 
demonstrated both cellular and subcellular uptake and enzymatic oxygenation of these two classes in 
adrenergic neuronal tissue. In the course of these studies we have obtained important new information 
which greatly extends and redefines the significance and scope of our strategic approach to the modulation ~ 
of adrenergic neuronal activity, a strategy which was highly hypothetical at the inception of the current ~ 
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grant period. We have investigated compounds of a number of additional classes at both the 
enzymological and whole-animal level, and have greatly extended the scope of our understanding of the 
enzymological and physiological constraints of this approach. The information we have obtained in these 
latter studies suggests several new directions for this work which, we feel, greatly enhances the 
significance and versatility of our program. The following report highlights our progress in each area with 
an evaluation of the extent to which our initial objectives have been met. We will divide this section into a 
discussion of each class of compounds for clarity. 
Sulfur-Cont.ainin& Compounds 
We have performed a number of pharmacological and neurochemical experiments with the a-
methylated and/or ring p-hydroxylated derivatives of phenyl-2-aminoethyl sulfide (i.e. P AES, MeP AES, 
HOP AES and HOMeP AES) over the course of the current project period (17). First, we have shown that 
all four of these sulfides possess significant antihypertensive activity in spontaneously hypertensive rats 
(SHR). We examined the time course of the cardiovascular activity of each of four derivatives over a 30 
min period, a 6 hr period, and in two-week chronic treatment experiments. We determined that in our 
earlier initial bioassays, the indirect tailcuff method for measurement of systolic pressure was giving 
erroneous readings. Using an indwelling carotid catheter, we were now able to continuously measure 
pulsatile blood pressure and show that the transient indirect sympathomimetic effect of these compounds (a 
measure of neuronal uptake) was strongly affected by the chemical structure of the derivative. Thus, in 
MeP AES, the alpha methyl functionality give rise to a heightened specificity for the adrenergic reuptake 
receptor. This is important new information which will be helpful in designing the next generation of 
these compounds. 
With the ability to reliably contrast time course of the antihypertensive activity in SHR of each of 
four derivatives ofP AES, we have now succeeded in obtaining evidence that the locus of bioactivity of 
our sulfides is principally in the peripheral adrenergic nervous system. This has been a basic presumption 
inherent in our postulated mechanism that the hypotensive activity of the sufides arises from competition 
with DA for DBM oxygenation resulting in dilution of peripheral sympathetic outflow. We find that the 
hydroxylated derivatives HOPAES and HOMePAES produced an antihypertensive effect a 75% of the 
size of that produced by the non-hydroxylated derivatives. Further, in as-yet-unpublished study, we have 
found an anorexigenic property of some of our sulfides which we have shown is unrelated to their 
antihypertensive activities and is certainly a CNS effect. Strikingly, the anorexigenic activity is restricted 
to those derivatives lacking a ring hydroxyl, with the ring-hydroxylated derivatives being completely inert 
as anorexigenic agents. These fmdings support the view that the hydroxylated derivatives of our sulfides 
have a much reduced ability to cross the blood-brain barrier, something which we assumed in our previous 
proposal by analogy with hydroxylated biogenic amines. We therefore feel much more justified in 
presuming that the similar hypotensive proflles of all four sulfides reflect the fact that there is little, if any, 
contribution to the antihypertensive activity of these compounds through CNS effects. We also note in 
this regards that a mechanism· which lowers NE levels will cause a lowering of blood pressure only by 
decreasing peripheral NE stores; in the CNS it is the elevation of NE levels which can cause peripheral 
blood pressure to drop. 
- In work designed to specifically examine both the cellular uptake of these derivatives and to 
explore the adrenergic reuptake specificity of the alpha-methylated derivatives, we have demonstrated (18) 
that all derivatives gain entrance to adrenergic neurons through the cocaine-sensitive catecholamine 
reuptake receptor. We fmd that not only is the uptake specific and pharmacologically-characterizable, but 
that this uptake seems to be followed by a rapid entrance of the derivatives into the vesicular pool of NE, 
as opposed to the cytosolic pooling observed with tyramine. This was highly significant, since such a 
process obviously would render the sulfides readily accessible for oxygenation by our target enzyme, 
DBM. Furthermore, bypassing cytosolic pooling may explain an apparent lack of MAO sensitivity of the 
bioactivity of our compounds (using our non-oral administration routes) despite the fact that PAES and 
HOP AES are good in vitro MAO substrates in our hands. 
We next turned to an examination of the ability of these compounds to directly gain entrance into 
neurotransmitter vesicles and to be oxygenated therein· by DBM, and to the biochemical consequences of 
these processes as they occur within vesicles. In a departure from the experiments we had planned to 
employ for these examinations, we decided to utilize bovine adrenal medullary chromaffm granule ghosts 
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instead of synaptosomal vesicles. This change in our plans was largely a result of the fact that this latter 
preparation from chromaffm granules has been extensively studied and characterized in a number of other 
laboratories over the past few years, with the result that chromaffm granules and chromaffm granule 
ghosts have become the preparations of choice for uptake studies. Unfortunately, when we began these 
studies, there was a report in the literature to the effect that the DBM of chromaffm granule ghosts did not 
utilize ascorbic acid as a cofactor in its catalytic oxygenative activity. This report cast doubt on the 
physiological significance of the membrane-bound DBM of chromaffin granule ghosts and meant that any 
experimentation we were likely to perform with this preparation, particularly those experiments involving 
activation by DBM, would be suspect. In work detailed in a recently-published 1.lllil!.~ paper (19) 
we reinvestigated this phenomenon and demonstrated that chromaffm granule ghost DBM does, in fact, 
utilize intravesicular ascorbic acid as a reductant with great facility. In addition, we defme conditions for 
the preparation and utilization of these ghosts for the study of DBM-dependent processes which is, in 
itself, a significant contribution to the literature. · 
With a thorough understanding of chromaffm granule ghost characteristics now in hand, we set out 
to answer the three critical questions regarding our presumed mechanism of action of our DBM-directed 
compounds; namely: 
Do the sulfur compounds could gain entrance to these ghosts (which are the widely accepted 
models for adrenergic neurotransmitter storage vesicles)? 
Are the sulfides oxygenated intravesicularly by DBM leading to a buildup of sulfoxide product? 
Does intra vesicular turnover of the sulfide reduce NE production in functioning vesicles by 
competing for DBM turnover? 
In work detailed in the attached 1.Bigl.~. manuscript in press (20) we have demonstrated that P AES is 
indeed rapidly concentrated within ghosts under pharmacologically-significant conditions. On the basis of 
reserpine experiments, we fmd that the uptake of P AES occurs both through the catecholamine transporter 
and also by passive diffusion of its free base through the granular membrane. Once P AES gains entrance 
to the ghosts, it is rapidly oxygenated by DBM and the product sulfoxide, P AESO, builds up in the 
intravesicular space. In other experiments in which equimolar concentrations of DA (which is of course 
the physiological substrate for granular uptake and DBM oxygenation) and P AES competed both for ghost 
uptake and enzymatic oxygenation by DBM, we showed that P AES was capable of reducing NE synthesis 
by as much as 50%. All requisite control experiments, such as demonstration that this effect is dependent 
on active DBM turnover, nonnal electron flux into the vesicle, etc. are documented in the paper. Thus, 
these experiments demonstrate conclusively that, at a subcellular level, using an accepted model for 
adrenergic neuronal neurotransmitter storage vesicles, P AES is indeed capable of reducing NE synthesis 
through the basic mechanism we have hypothesized. 
With these results with chromaffm granule ghosts in hand, we next wished to tum to the more 
complete system of adrenergic cells in culture in order to demonstrate these basic processes of uptake and 
enzymatic conversion of our compounds. To this end, in 1987, we established a tissue culture laboratory 
in our research group. We have developed and adapted literature preparative methods for the primary 
culture of bovine adrenal chromaffm cells. We are now able to attain homogeneous populations of 
chromaffin cells in quantities which match those of the best preparations found in the literature, and which 
remain viable for an extended period (greater than 18 days). In addition, utilizing a starter culture obtained 
from Dr. Lloyd Greene, a pioneer in the area, we have continuously cultured and passaged the PC12line 
of rat pheochromocytoma cells for more than a year. This cell line originated from a tumor of the 
chromaffm cells of the rat adrenal medulla, and is an excellent and very well-studied model for adrenergic 
neurons. (21 ). 
We are currently carrying out initial uptake experiments in cell cui~. For theses experiments we 
are using HOP AES and have just completed the synthesis of HOP AESe; these derivatives are detectable 
using the very sensitive HPLC/electrochemical detection ~hniques we have worked out in our laboratory. 
Once the uptake experimen&s are complete, we will wish to directly demonstrate the effects of our 
compounds on NE synthesis. An important operational note is that we have now established reliable 
conditions under which both media ascorbate and oxygen levels can be maintained and measured during 
the period necessary for experimentation This is a non-trivial point for the types of experiments we wish 
to do with the sulfides and selenides. 
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Taken together, these results with derivatives of the sulfur-containing class ofDBM substrate 
analogs have considerably advanced our understanding of the mechanisms by which they exert their 
antihypertensive activity. While these studies are not as yet complete, we feel that our hypothesized 
mechanism of action - adrenergic uptake, neurotransmitter vesicular uptake, DBM oxygenation to form 
sulfoxide and exocytosis of NE now diluted by the presence of receptor-inactive sulfoxide in response to 
nerve fning - is on much fumer ground than it was at the start of the current project ~riod. 
Selenium-Contajnin& Compounds: Tumover-de,pendent Cofactor Pe,pletion 
During the cUITent project period, we completed a thorough characterization of, and published 
(20,22,23), the unique enzymological characteristics of DBM-catalyzed turnover of our prototype 
selenide, phenyl-2-aminoethyl selenide (P AESe). We fll'St confinned that P AESe is indeed an excellent 
substrate for DBM. Enzymatic oxygenation produces phenyl-2-aminoethyl selenoxide (P AESeO), with 
kinetic parameters comparable to those for oxygenation of other active substrates - e.g., the cognate 
sulfide, phenyl-2-aminoethylsulfide. As expected, oxygenation ofPAESe by DBM follows the normal 
'reductive oxygenation pathway; i.e., it exhibits absolute requirement for oxygen and electron donor, the 
1:2:1 oxygen:electron:product stoichiometry diagnostic for monooxygenases, and stimulation by the DBM 
activator, fumarate. 
As mentioned in BACKGROUND, what is remarkable about the processing of P AESe by DBM is 
that the enzymatic product, P AESeO, possesses a redox capability unlike that of any other DBM product 
P AESeO reacts non-enzymatically with reduced ascorbate, giving back one molecule of P AESe and one 
molecule of fully oxidized ascorbate. During this CUITent period we thoroughly characterized this non-
enzymatic recycling reaction,and showed that it is a facile, stoichiometric process. Thus, we have clearly 
shown in in-vitro experiments that once enzymatic processing ofP AESe by DBM begins, newly formed 
P AESeO is recycled back to P AESe, and this cyclic oxidation/reduction pathway continues until reduced 
ascorbate is depleted. Since reduced ascorbate is an essential cofactor for DBM, this in-situ depletion of 
reduced ascorbate prematurely terminates enzymatic activity. 
We next turned to experiments in chromaffm vesicle ghosts in order to examine the consequences 
of this selenoxide recycling on ascorbate levels in the presence of the b-561-dependent ascorbate recycling 
system. We viewed such experiments as crucial, since while our solution results certainly demonstrated 
novel biochemistry for the selenide substrate, a physiologically meaningful rationale for drug design can 
only be established by demonstrating such ASCH2 depletion even in the presence of the physiological 
ASCH2 recycling system. Our expectation was that turnover of our selenidcs could well "short circuit" 
the b-561 system, since our in vitro work had revealed that no trappable semidehydroascorbate is formed 
during the nonenzymatic reaction of selenoxide and ascorbate. This was a highly significant fmding since 
it is now generally accepted that semidehydroascorbate is the immediate product of DBM turnover, and it 
is this species which is recycled by b-561 at the expense of extravesicular ascorbate. We reasoned that if 
indeed the selenoxidelascorbate redox reaction is a two-electron process in a kinetic sense (i.e., occurs 
without significant buildup of semidehydroascorbate ), then accumulation of fully-oxidized ascorbate in the 
vesicle would occur as selenide is processed Since fully oxidized ascorbate cannot be re-reduced by b-
561, the net result of selenide oxygenation is thus the effective depletion of an essential cofactor for NE 
production. [It is noteworthy that the oxidation of catechols by selenoxides is nonnally viewed as a two-
electron oxidation process in organic chemistry (24,25).] 
The results of our chromaffm vesicle ghost experiments were fully consistent with this expectation 
(20,23). P AESe indeed causes a turnover-dependent depletion of reduced ascorbate in fully competent 
vesicle ghosts; as expected, this does not occur with the analogous sulfide substrate, where the sulfoxide 
product - which is non-reactive toward ascorbate -builds up with time. Significantly, these experiments 
also established that the selenides are actively transported across the vesicle membrane, and are readily 
oxygenated by the membrane-bound DBM present in the vesicles. Under conditions of our experiments, 
vesicular reduced ascorbic acid stores were reduced by about 60%, and NE production was greatly 
reduced. Thus, our selenides exhibited precisely the effects we had predicted from our solution studies. 
A further observation was that the competition exhibited by P AESe against DA (the physiological 
substrate) for DBM oxygenation allowed the buildup_ of significant concentrations ofDA withiil the 
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vesicles. This fmding might contribute to the potency of these compounds, since DA is known to cause a 
powerful vaso-dilatory effect via direct DA-1 receptor activation. 
In a thorough phannacological bioassay study with the selenides, which was published within the 
past few months (26), we have clearly documented the potent antihypertensive activity ofPAESe, the 
prototypic derivative of this series. We followed groups of SHR (control and drug-treated) over a two-
week or more period, with dosing on a daily basis and with measurement of blood pressure, heart rate, 
and body weight over the entire period. In addition, we determined catecholamine levels in hearts of both 
control and experimental animals at the end of the experimental period. The data shows that P AESe 
exhibits a marked, dose-dependent antihypertensive effect in SHR, with as much as a SO% reduction in 
blood pressure beginning ca. 48 hrs. after the ftrSt dose and extending for more than two weeks. We 
found that the marked antihypertensive activity of P AESe in SHR occurs concomitant with a reduction in 
heart rate, heart weight, and heart catecholamine stores. An initial, short duration indirect 
sympathomimetic effect also occurs which is blocked by cocaine, thus suggesting that adrenergic neuronal 
uptake does occur through the same mechanism as that determined for the sulfur-containing compounds. 
Taken together, we view our results with P AESe as illustrative of a novel strategy for designing 
modulators targeted at an enzyme such as DBM. The strategy entails design of an alternate substrate such 
that it will be readily converted by the target enzyme to a product, which is th~n capable of causing local 
depletion of an essential cofactor for the target enzyme itself. Such a strategy of turnover-dependent 
cofactor depletion is conceptually quite distinct from outright inhibition of the enzyme of interest, and 
might represent an especially useful approach to modulating compartmentalized cofactor-dependent 
enzymes for therapeutic purposes. 
Finally, it is important to note that potential phannacological applications of selenium-containing 
compounds must take into account any possible toxicological effects. We report in our J .PhannExpTher 
report (26) that there was no discemable effect on serum enzymes, electrolytes, or circulating metabolites 
in test animals treated chronically with large doses of P AESe. We see no indications at all of the 
characteristic hepatotoxicity patterns reported for inorganic selenium toxicity (27). 
In sunurwy, we feel that our hypothesized mechanism of action - adrenergic uptake, 
neurotransmitter vesicular uptake, DBM selenoxygenation, ascorbate recycling and the consequent 
lowering of endogenous NE levels -- is on much fumer ground than it was at the start of the current 
project period. 
N-DealiQ'lation. Olefin Oxyeenation, and Mechanjsm-Baseci Inactivators 
As mentioned in BACKGROUND, we have discovered that DBM readily catalyzes oxidative N-
dealkylation of N-phenylethylenediamine (PEDA) and its derivatives [e.g. N-methyl-N-
phenylethylenediarnine (N-MePEDA]. During the current project period we carried out a thorough 
mechanistic study of the novel N-dealkylation activity for DBM (28,29) [We had discovered this reaction 
at the very end of the previous project period.] 
The products ofPEDA N-dealkylation were quantitatively identified as aniline (or N-methylaniline 
for N-MePEDA) and 2-arninoacetaldehyde, the latter compound being successfully trapped using NaBH4 
reduction followed by N-succinimidyl p-nitrophenylacetate (SNP A) derivatization, and identified by 
HPLC and mass spectroscopy. In contrast, ether analogs ofPEDA, i.e., phenyl-2-aminoethylether 
(PAEE) and its p-hydroxy derivative (p-OHPAEE), as well as 2-phenoxycyclopropylamine, are not 
substrates but are competitive inhibitors. Furthennore, 2-methyl-2-(anilino )-1-arninoethane (b-MePEDA) 
did not exhibit measurable substrate activity with DBM, in contrast to the excellent substrate activity of 
sulfur analog of b-MePEDA, 2-methyl-2-(phenylthio)-1-am.inoethane (b-MePAES). DBM is inactivated 
during the N-dealkylation reaction in a time- and concentration-dependent manner, a phenomenon that has 
not, to our knowledge, been observed for any other oxygenase-catalyzed N-dealkylation reaction. Both 
PEDA and N-MePEDA, as well as b-MePEDA, inactivate DBM under turnover conditions. The 
inactivation exhibited pseudo-frrst order saturable kinetics and expected protection by the DBM substrate, 
tyramine. No reappearance of enzyme activity was observed after extensive dialysis. Radioactive labeling 
experiments with ring-tritiated PEDA showed incorporation of non-dialyzable radioactivity into DBM in 
the expected amount, consistent with covalent attachment of a reactive species derived from PEDA to the 
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DBM active site during enzyme inactivation. Although, aniline, N-ethylaniline, N-(2-fluoroethyl)aniline, 
m- and p-anisidine, p-toluidine and 5-hydroxyindole were found not to exhibit detectable DBM substrate 
activity., all of these inactivated the enzyme under turnover conditions. The isotope effect on partition ratio 
measured for di-deuterated PEDA was found to be a reflection of an isotope effect on Vmax and not on 
kinact. 
Our results provide a strong support for the conclusion that DBM processing of PEDA and its 
cognates involves initial fonnation of a nitrogen cation radical, and it is this species which partitions 
between turnover and on the one hand or mechanism-based enzyme inactivation on the other. Results with 
ring-deuterated and ring-tritiated PEDA revealed that the amount of radioactivity incorporated into 
covalently-inactivated DBM by ring-tritiated PEDA is in agreement with that expected for covalent 
attachment of the para carbon to the protein. An 180 labeling study was carried out to test for oxygen 
rebound into the aminoacetaldehyde product, and the results demonstrated that the aldehyde oxygen of 
enzymatically-produced 2-aminoacetaldehydc exchanges very rapidly with solvent water, in agreement 
with literature reports. · 
Based on our mechanistic studies with heteroatom and olefinic substrates, we proposed a unified 
mechanism for all DBM-catalyzed monooxygenations, which is discussed in detail in papers published 
during the current grant period (28,29). Briefly, benzylic oxygenation by DBM proceeds through the 
unified intermediacy of a species with cationic and/or radical character when either methylene, olefm, 
carbinol, sulfur, or nitrogen is in the benzylic position. Oxygen. transfer from copper to this species 
Occurs readily in the case of carbon; similarly, the strong tendency of the sulfur cation radical towards 
sulfoxidation produces solely the sulfoxide and not the S-dealkylated product For nitrogen, N-
dealkylation of the cation radical species is a favored process and occurs readily. Thus; in essence, 
inactivation by PEDA- and P AME- type compounds represents a trapping of cation radical species formed 
along the N-dealkylation or olefm oxygenation pathway. Consistent with this mechanism, DBM is unable 
to carry out the oxidative 0-dealkylation ofphenylarninoethyl ethers under the usual reaction conditions, 
even though these bind very well to the active site and are competitive inhibitors for the enzyme. We have 
designed other novel substrate types for trapping such species and hope to examine them in detail during 
the coming grant period. 
In bioassay work with PEDA which is still ongoing (30), we have observed several characteristics 
of PEDA's hypotensive activity which are quite distinct from that of the sulfides and selenides. First, we 
have observed not only depletion of NE and EPI, but also a significant rise in heart DA levels. Secondly, 
PEDA's hypotensive activity is much more prolonged, extending for six to seven days after drug 
withdrawal. Cearly, we are most interested in establishing that these differences do, in fact arise from a 
suicide inactivation mechanism being operative with PEDA, something we plan to explore in the coming 
project period. 
Turning to our olefinic compounds, our laboratory was the fU'St to demonstrate (in 1983 during our 
first project period; ref 14) that properly-designed olefins- such as our prototype 1-phenyl-1-
aminomethylethene (PAME)- are epoxidized readily by DBM, that these are potent suicide inhibitors for 
DBM, and that mechanism based inactivation arises from a species with radical and or cationic character 
along the epoxidation pathway (14,29). Other groups in both academia and the pharmaceutical industry 
have made analogs of such olefms and some of these are very facile suicide inactivators indeed. We have 
examined and characterized kinetically and mechanistically a host of olefins based on the P AME structure; 
we now have in hand optimized olefmic inhibitors, some of which are sinele tymover jnactiyators for 
DBM (ie. have a partition ratio ofunity).(31). We are particularly anxious to explore the pharmacological 
properties of such compounds. 
In a direction which we did not anticipate, we have found a number of non-aromatic substrates 
which are very readily oxygenated by DBM (31). Moreover, we have discovered an entirely new 
oxygenative competence for DBM with non-conjugated olefins- the ability ofDBM to readily carry out 
allylic hydroxylation. In a communication in press in J.Am.Chem.Soc (32) we report this fU'St example of 
allylic oxygenation using the substrate 2-(1-cyclohexenyl)ethylamine, we demonstrate that this reaction is 
highly facile and stereoselective, we d~tennine the absolute configuration of the enzy~tically-produced 
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alcohol using a novel chiral resolving agent developed in our laboratory(33) together with nmr analysis of 
the diastereomeric adducts using the Mosher model (see refs 32 and 33 in Appendix) 
Amine-Iennjnus-Modjfied Compounds. 
During this project period, we designed several substrate analogs in which the primary amino 
tenninus of the alkyl chain is replaced by a nitrogen-containing heterocyclic nucleus (34). For example, 
we demonstrated that 4-hy~xy-benzylimidazole (4-HOBI) is a facile substrate for DBM oxygenation. 
The enzymatic oxygenation of 4-HOBI results in oxygenolytic cleavage to produce 4-
hydroxybenzaldehyde and imidazole. In contrast, when the tenninal amino is replaced with pyrazole, a 
functionality which is uncharged at the pH of the DBM reaction and which is known to be a good copper 
ligand, the analog possesses potent DBM competitive inhibitory activity. Evidence in hand is suggestive 
that the pyrazole is interacting with the copper at the active site of DBM. We consider these results to have 
important implications to the future design of DBM-activatable "~drugs" possessing amino-tenninal 
heterocycles which may impart adrenergic receptor agonistic or antagonistic activity to the enzymatic · 
products. 
We have also synthesized several phenylethyl alcohols and phenyl-ethanol sulfides (the non-
amino-containing alcoholic analogs ofphenethylamine and PAES, respectively). We have recently found 
these compounds to be appreciable enzymatic substrates gnlx in~ abSence gf fumarate. Fumarate, as 
well as other di-carboxylic acids, are known stimulators of DBM catalysis. The fact that substrate analogs 
possessing a primary alcohol in place of the normal positively-charged, primary amino tenninus exhibit 
substrate activity only in the absence of fumarate suggests that fumarate is intimately involved in substrate 
binding of positively charged substrates. · 
Unsuccessful Work and Unfinished Busjness. 
Although we feel that we have made good progress during the current project period, and in 
several instances have exceeded our own expectations, there are some areas in which we were less 
successful. 
We have not extended our animal studies as much as we had planned with suicide substrates. We 
made the decision that we wanted to complete kinetic characterization of these classes to select those which 
would have the most promising from phannacological potential; this we have now done and we will focus 
on animal and cellular level studies with these compounds during the coming year. 
We have been unsuccessful in rmding substrate activity with carboxyl-group-containing analogs 
designed to explore the "salt bridge" theory of the activating effect of fumarate (see pp. 38-39). Either our 
substrate analog· designs were inappropriate, or the basic idea was erroneous. After considering the 
comments of the study section, we also decided not to pursue substrate analogs of the fused-ring type or 
those containing the pyridynyl nuclei. 
Finally, we have not proceeded very far with the eNS-targeted pro-pro-drugs we had planned to 
examine. First of all, we have had considerable difficulty in the preparation of the (S,S) diastereomer 
which would be the most important of the four diastereomers. Secondly, as was noted in the Study 
Section review, there was a fairly tenuous argument for their utility. However, ph~ological research 
on central adrenergic reflex pathways which has progressed over the past few years may re-kindled our 
interest in this approach in the future. 
D. METHODS 
Selenium-Contajnin~ Compounds. 
The unique aspect of this class of compounds arises from our hypothesis that they cause 
modulation of adrenergic neuronal activity through the novel strategy of turnover-dependent local depletion 
of the essential DBM cofactor, reduced ascorbate (ASCH2 )· Because of this unique mechanism of 
ASCH2 depletion, we recognize that compounds of this class may have wide ranging applications in 
neuroscience, in addition to their potential as hypotensive agents. Therefore, it is critical that we conf.trm 
tJ 
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our hypothesized mechanism of action of the selenides using increasingly demanding criteria, and that we 
demonstrate this process directly in cell culture. There are three aspects to our proposed work: 
A. Cultured Cell Experiments. 
Our fmding in chromaffm granule ghosts that P AESe depletes intra vesicular ASCH2, even in the 
presence of the b-561-mediated ascorbate recycling system, must be expanded to a full characterization of 
this process - and its consequences on local and cytosolic ASCH2 levels -- in functioning cells in culture. 
We have already obtained preliminary data confmning uptake ofHOPAESe (as well as HOPAES) into 
cultured adrenergic neuronal cells (see PROGRESS REPoRT). We have also established a viable tissue 
culture laboratory here, and have established reliable conditions under which both media ascorbate and 
oxygen levels can be accurately maintained and measured during the period necessary for experimentation. 
In these experiments we want to establish three things. First, we want to characterize the time 
course of selenide uptake. Next, we want to show that selenides do, in fact, get further localized into the 
chrornaffm vesicles within the cells, and detennine the extent of such localization. Third, we want to 
demonstrate that it is. indeed local ASCH2 - i.e. within the vesicles where DBM turnover occurs - which 
is depleted by the selenides. This latter point is a subtle but important one, since cytosolic ASCH2 does 
serve as the electron shuttle for reduction of the b-561located in the vesicle membrane, with cytosolic 
ascorbate cycling between ASCH2 and semidehydroascorbate and electrons ultimately coming from 
NADH by way of semidehydroascorbate reductase. (More complete discussion is in Appended papers 
#2,3,6,8). It is within the vesicles where we expect newly-formed selenoxide to react readily with 
intravesicular ASCH2 to fonn "dead-end" fully oxidized ascorbate. We must determine to what extent 
these expectations are borne out in functioning, cultured cells. 
We plan to utilize the well-establishedPC-12 pheochromocytoma cell line in these investigations. 
PC-12 is an ideal neuronal model for these studies since the day-to-day maintenance of this well-
characterized cell line is both much cheaper and much less time-consuming than the primary adrenal 
chrornaffm cell cultures with which we had originally planned to work. Furthennore, PC-12 cells have 
been shown to possess the requisite enzymes of NE synthesis, including DBM (35), require ascorbate for 
maximal NE synthesis (21}, and are homogeneous, producing m NE (unlike the heterogeneous primary 
cultures which are composed of both NE- and BPI-synthesizing cells). In order to characterize the time 
dependence of selenide uptake, and detennine its subcellular localization after uptake, we will fll'St utilize 
tritiated HOP AESe, which we have found to be the selenide which is most easily ring tritiated in our hands 
[We describe our tritiation procedure in detail in Ref28]. In addition, by employing the very new 
technique of ICP/MS with the help of our collaborator, Professor Richard Browner (See Collab 
Arrangements}, we anticipate also being able to quantitate picomole (per ml; ie.nM) quantities of illX 
selenium-containing compound, such as the refmed derivatives noted below, without the necessity of 
tritiation. 
Our typical protocol will be to add various concentrations of selenide to g. 1 X 1 o6 cells in 
multi well plates, and after an appropriate incubation, stop the reaction by removal of the media, washing 
with ice-cold blank media, and cell harvesting. Since we have developed HLPC procedures for the 
separation of the test compounds from catecholamines and other cellular constituents (see appended 
reprints), we will be able to easily identify and quantify (by scintillation counting or ICP/MS) both the 
original selenide and any radiolabeled (or Se-containing, when we use ICP/MS)) metabolites. Uptake will 
be characterized as to the effects of pretreatment of the cells with, for example, phannacologically-
significant concentrations of cocaine, a known uptake1 blocker, or in Na deficient media; this will correlate 
the characteristics of cellular uptake ~th results from whole-animal phannacological experiments we have 
already performed. Analogous experiments wherein cell collection is followed by subcellular fractionation 
will be done to determine the intracellular localization of selenides after uptake. This is easily performed 
since the use of differential centrifugative procedures and enzyme· markers for isolated subcellular • 
organelles have been long-established in these PC-12 preparations. Entirely analogous experiments will 
be performed to examine the extent and localization of ASCH2 depletion. As detailed in our recent 
JBiolChem papers (refs 19, 20; see Appendix) we have developed the requisite procedures for accurate 
quantitation of intra- and extra-vesicular ASCH2 levels, as well as for measurement of DBM activity, in 
the isolcfled fractions. 
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Finally, in similar experiments in PC-12 cells, we will use the information gained in the above 
studies on the time course of uptake and maximal ascorbate depletion to "preload" cells with the test 
compound in order to demonstrate pharmacologically-significant exocytotic release of the intravesicular 
contents from these cells. Thus, stimulus of pre-loaded cells with the proper levels of acetylcholine or 
nicotine will be followed by sampling of the bathing media and quantitation of the released test compounds 
and metabolites by HPLC/scintillation counting. In addition, the ability of the test compound to compete 
with DA, the immediate precursor to NE, for cellular uptake, vesicular uptake, and DBM oxygenation will 
be testable using the same procedure (with the analysis of released NE) and will be highly instructive in 
validating our proposed mechanism. 
B. Stereochemical Correlation and "Fine Tunini" of Ascorbate;-Depletion. 
We propose to utilize two approaches to manipulation of selenide-dependent ASCH2 depletion in 
order to: a) further establish the absolute dependence of this process on DBM-catalyzed turnover; and b) to 
probe whether this process can be manipulated by judicious choice of the particular selenide substrate. In 
the first approach, we will take advantage of the enantiomeric selectivity ofDBM for (S)-alpha-methylated 
derivatives of selenides (i.e. S-MeP AESe) - an unexpected enantioselectivity which we discovered last 
year. The second approach will make entail synthesis of, and biochemical characterization of ascorbate 
depletion by, more refmed derivatives ofPAESe. 
We will perfonn these studies using bovine adrenal chromaffm granule ghosts, a preparation with 
which we now have considerable experience. These ghosts are an ideal model for adrenergic 
neurotransmitter synthesis and storage since they possess membrane-bound DBM, the catecholamine 
uptake transporter, the H+-translocating ATPase, and most importantly, the cytochrome.bS61 ascorbate .. 
dependent electron transporter. Using the methods we have published (19,20,23) we will be able to 
measure vesicular uptake and concentration, measure DBM turnover, and measure the effects of these 
compounds on intravesicular ascorbate levels. 
In the experiments with the enantiomers of MeP AESe, we will be looking for a sharp contrast in 
the behavior of the S vs R enantiomer; only the former should be processed by DBM within the ghosts 
leading to ASCH2 depletion, while with the R enantiomer - which we now know has virtually no 
substrate activity with DBM --no such depletion should occur. We think that there is a good chance that 
both enantiomers will be taken up readily into ghosts, since we there are suggestions in the literature that 
vesicular uptake is much less discriminating toward stereoisomers than cellular uptake into the chromaffm 
cell. [Note that S-MeP AES is stereotopically analogous to the naturally occUlTing a-substituted biogenic 
amines like (+)-amphetamine]. However, even if uptake discriminates between these enantiomers, we can 
still do these experiments by simply opening and resealing the ghosts in the presence of the selenides to 
initiate the experiments, something which we now have much experience. In fact, it is precisely for this 
reason that we plan to do these experiments in ghosts as opposed to PC-12 cells; ghosts are readily opened 
and resealed by us and many others in the literature for the purpose of tailoring their internal contents. Our 
protocols here for incubation, turnover, analysis of intravesicular ASCH2, etc are straightforward 
following exactly our published procedures. Success in showing a direct cOITClation between the 
enantioselectivities of enzymatic turnover and ASCH2 depletion even in the presence of the ghosts' fully 
functional bS61 recycling system will represent very strong evidence for a direct link between these 
processes. [We have in hand quantitities of enantiomerically pureR and S MeP AESe, both from 
stereospecic synthesis and from diatereomeric HPLC resolutions using our novel chiral derivatizing agent · 
(33)]. 
The ability of dipheny lselenoxide to act as mild oxidizing agents has ·been explored recently by 
synthetic organic chemists. It has been demonstrated that while the electron donating substituents in the 
aromatic ring will decrease the oxidizing power and generate more selective oxidizing agents, electron 
withdrawing groups yield more powerful, less selective oxidizing agents (36). We will therefore compare 
both para-F-P AESe and para-HO-P AESe as DBM substrates and as turnover-dependent ascorbate 
depletors both in vitro and in ghosts. [We have pHOP AESe in hand, synthesized from 
pMeOphenylmagnesium bromide plus metallic selenium to give p-MeOphenylselenol, followed by our 
standard oxazoline reacti0n and fmally acid hydrolysis of the acetamide and debloc~g with BBR3; p-
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FP AESe will be synthesized using the same synthetic pathway]. We know that p-HOP AESe is an 
excellent DBM substrate; we anticipate p-FP AESe will be a slower substrate based on our kinetic studies 
on a host of ring substituted P AES derivatives which we carried published in 1981. On the other hand, 
the p-HOP AESeO sulfoxide product should be a poorer ASCH2 recycler than p-FP AESeO. What will be 
the net kinetic effect on ASCH2 levels both under in vitro assay conditions and in ghosts? We would like 
to know whether we can, in fact, manipulate turnover-dependent recycling - in a kinetic sense --by 
judicious choice of the particular selenide substrate. This would be very useful for many future 
applications of these selenide compounds to modulate adrenergic outflow. 
C. Determinations of Effective Tissue Concentrations. 
We wish to correlate phannacological data on the effect of selenides on isolated tissues - which is 
being obtained by our collaborators at the University of Georgia (Drs. Hartle and Tackett; see 
Collaborative Arrangements) - with our whole animal data on the hypotensive activity of the selenides. 
For this purpose, it is essential for us to carry out a limited investigation of the tissue concentrations of 
P AESe reached in both acute and chronic dosing in SHR. The methodology we will employ in these 
studies is that of straightforward pharmacodynamic investigations, and we will use the ICP/MS technique 
which allows the determination of picomole quantities of selenium-containing compounds. Thus, 
spontaneously hypertensive rats (SHR) will be dosed either acutely or chronically with doses of P AESe 
(and/or more interesting derivatives) and sacrificed at an appropriate time. Samples of heart, kidney, 
adrenal, brain, and blood plasma will be collected and analyzed for the content of P AESe and its 
metabolites. Of particular interest will be the concentration of P AESe in blood plasma, since it is the 
question of effective concentration of these compounds at adrenergic receptors which we want to know 
(the majority of adrenergic receptors responsible for the maintenance of blood pressure are in direct contact 
with blood plasma). 
Sulfur-Containin& Compounds. 
This class represents our simplest strategic approach to the modulation of adrenergic neuronal 
activity. We plan to utilize our extensive understanding of the enzymology and pharmacology of these 
sulfur-containing substrates in limited experiments which parallel very closely those just described for the 
selenide class. Briefly, the three aspects of our proposed work are: 
A Cultured Cell Experiments: Using PC-12 pheochromocytoma cells, we will examine the 
cellular uptake, vesicular uptake, enzymatic sulfoxidation, and exocytotic release of a HOP AES (which we 
have found can be most easily tritiated), in cultured cells and subcellular fractions. In these experiments, 
note that we will be able to directly measure the product sulfoxide, HOPAESO, unlike the situation in the 
case of the selenium-containing analOgs where no appreciable product buildup occurs due to rapid back 
reaction with ASCH2. Note also that the sulfides are not expected to cause depletion of imravesicular 
ascorbate, since the sulfoxidcs do not oxidize ASCH2 to "dead-end" fully oxidized ascorbate. We have 
clearly demonstrated these two sharp distinctions between the sulfides and selenides in chromaffm ghost 
experiments (Ref 15, 20; Appended papers #1 & 3), which we consider hallmarks distinguishing their 
respective mechanisms of action, and confumation in functioning cells is of major importance in 
confmning our hypotheses. 
B. Pharmacodynamic Investi~ations: As discussed in PROGRESS REPORT, we now have in hand 
data on the anorexigenic effect of only the non-hydroxylated P AES derivatives, which supports our design 
hypothesis that HOP AES and HOMeP AES have a much reduced ability to cross the blood brain barrier. 
We plan to confmn this contention by administering radiolabeled HOP AES and HOMeP AES i.p. to SHR 
at doses which we have found cause appreciable antihypertensive effects, and then determining organ and 
tissue distributions after sacrifice. We feel that these experiments, though laborious, are quite important, 
since a primarily peripheral locus of action is an important facet of our proposed mechanism, and 
confmnation of minimal CNS access is an important consideration in any eventual clinical application of 
hydroxy derivatives of many of our compounds. 
C. Stereochemical Selectiyity: Here, once again, we will examine the correlation between the 
enantioselectivity ofDBM sulfoxidation for only S-MePAES with the effects ofR- vs S-MePAES in 
SHR, in PC-12 cells and in granule ghosts in order determine at the cellular and subcellular level whether 
or not enantiomeric specificity affects-binding, uptake, and hypotensive activity in w~ole-animals. As is 
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the case with the Me-selenides, we have in hand quantities of enantiomerically pure R and S MeP AES, 
both from stereospecific synthesis and from diastereomeric HPLC resolutions using our novel chiral 
derivatizing agent (33). 
Qptimi~ed Suicide Substrates: Bioassay. Cellular and Subcellular Eyaluations 
Most of our detailed bioassay and subcellular work to date has focused on our substrate analogs 
for DBM Over the past project period, we have examined and characterized -- kineti~ally and 
mechanistically - numerous derivatives of two basic classes of novel mechanism-based DBM inactivators: 
olefms based on the P AME structure, and N-dealkylation inhibitors based on the PEDA structure (See 
Progress report; refs 28,29; Appended papers #7,10). We wish to emphasize that we have maintained in 
these inhibitors 'the structural features necessary for solubility and uptake; this reflects our desire to 
evaluate our inhibitors for phannacological potential, not just for mechanistic purposes. 
In the case of olefms, we have found that out of numerous PAME derivatives, para-F-PAME is an 
active, single turnover inactivators for DBM (ie. it has a partition ratio of unity).(31). In the case of 
PEDA derivatives, beta-Me-PEDA is also an active mechanism-based inactivator with a very low partition 
ratio (about 50). We will therefore begin with these two compounds and eval~te them at the animal, 
cellular and subcellular levels using our usual protocols. · 
In preliminary bioassay work with PEDA (30), we have observed several characteristics of 
PEDA's hypotensive activity which are quite distinct from that of the sulfides and selenides. First, we 
have observed not only depletion of NE and EPI, but also a significant rise in heart DA levels. Secondly, 
PEDA's hypotensive activity is much more prolonged, extending for six to seven clays after drug 
withdrawal. Clearly, we are most interested in establishing that these differences do, in fact, arise from a 
suicide inactivation mechanism being operative, and thus we are particularly anxious to examine b-
MePEDA and p-F-PAME. As we have done with our sulfides and selenides, companion experiments will 
examine the uptake, enzymatic oxygenation, and inactivation kinetics of each derivative in chromaffin 
granule ghostS. 
The contrast between the magnitudes and time courses of the antihypertensive activities (and the 
attendant changes in NE tissue levels) for compounds designed to inactivate DBM in comparison to the 
effects already observed for the substrate-analog classes will allow us to critically assess the ultimate value 
of either approach. Similarly, the contrast between the subcellular organellar effects of the mechanism-
based inactivators n. the substrate analogs will allow us to assess and compare their neurochemical 
characteristics. We therefore feel that the results of these comparative studies will be of considerable 
value. 
New Compounds 
In this subsection, we propose to synthesize and examine new classes ofDBM-targeted 
compounds. We will first examine their detailed enzymology, including kinetic evaluations, 
determinations of the turnover-dependence and reversibility or irreversibility of inhibition, etc. For those 
compounds whose structural features, chemical properties and enzymological parameters suggest that they 
would be promising candidates for bioassay, we will use our standard SHR antihypertensive assay 
method. Compounds which exhibit appreciable activities in these assays would then be examined at the 
cellular and subcellular levels. · 
A. Inhibitors Desi&ned to Generate Michael Acceptors Upon DBM Monooxywation: 
In our previous studies we have demonstrated that the sulfur analog of pheny lethylamine, P AES, 
and its ring and side chain substituted compounds are excellent substrates for DBM, and the products have 
been identified as the corresponding sulfoxides (10,15). In addition, our recent work has established that 
compound Xa, in which the aromatic moiety of the phenylethylamine has been replaced with a 
cyclohexene, is an excellent substrate for DBM with the steady state kinetic parameters comparable to that 
of the best DBM substrate, tyramine (32). Therefore, it is likel~ that sulfur containing compounds such as 
X could be good substrates for DBM, and DBM monooxygenation will result in the generation of a 
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corresponding sulfoxide (Xa) in the DBM active site. It is well known that alpha, beta unsaturated 
sulfoxides are extremely reactive towards nucleophiles and undergo Michael type addition reactions under 
mild conditions. Since DBM monooxygenation of X generates a highly reactive alpha, beta unsaturated 
sulfoxide (Xb) in the active site of the enzyme, X could be a potential turnover-dependent irreversible 
inactivator for DBM as shown in the scheme below, if an active site nucleophilic moiety is properly 
oriented for covalent attachment These compounds will be synthesized by alkylating the potassium salt of 
thiocyclohexanone with 2-bromoethylalcohol (37) and then converting the corresponding alcohol to the 
terminal amine by standard techniques. If we encounter any problems in the above synthesis (thiones are 
sometimes difficult to work with) the following synthesis will be used. Cyclohexanone will be reacted 
with two equivalepts of2-aminoethylmercaptan and the product (the thioacetal) will be oxidized with one 
equivalent of sodium periodate to yield the desired product. Depending on the outcome of our inhibition 











B. Inhibitors Desi~ed to Undereo Pummerer I:® Rearran&ement Upon PBM Mediated 
Su tfoxjdation. 
We have recently discovered that properly designed aliphatic sulfides possessing an aminoethyl 
moiety are good substrates for DBM [for example both butyl2-aminoethyl sulfide as well as cyclopentyl 
2-aminoethylsulfides are good substrates for DBM (38)]. In addition, as noted above, a cyclohexene ring 
confers excellent substrate activity for DBM. Therefore, it is likely that compounds such as XI will be 
substrates for DBM. If these compounds are substrates for the enzyme, the DBM-mediated 
monooxygenation should yield the corresponding sulfoxide product (XIa) similar to the case of the 
respective aromatic cognates or aliphatic sulfides . . Due to the presence of a carbonyl group at the beta 
position, the alpha hydrogen of the sulfoxide Xla is acidic which facilitates the "Pummerer 
rearrangement". [Compounds bearing an acidic hydrogen alpha to a sulfoxide functionality, are known to 
undergo Pummerer rearrangement under mild conditions; for example, the beta-keto sulfoxide XII 
undergoes Pummerer rearrangement with aqueous acids or other acidic reagents at room temperature to 
form the hemimercaptal of an alpha-keto aldehyde (39)]. As shown in the scheme below, Pummerer 
rearrangement of the sulfoxide product Xla will result in an extremely reactive species (XIb) which could 
be attacked by a side chain nucleophile in the active site of the enzyme to inactivate the enzyme 
irreversibly. We note however that such a rearrangement will be dependent on the presence of a properly 
oriented basic residue in the enzyme active site to abstract the acidic alpha hydrogen. Compound XI will 
be synthesized by treating commercially available 2-chlorocyclohexanone with 2-mercaptoethanol under 
basic conditions and then converting the terminal hydroxyl group to an amine by standard techniques. 
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C. Inhjbjtors Desi'"ed to UnderKo f2.31 Simatro.pic RearranKement: 
Our work has amply demonstrated the ability of DBM to carry out facile selenoxidation of P AESe 
and its derivatives (22). Recent work by Walsh ~ .al has demonstrated that flavin enzyme, cyclohexanone 
oxygenase, is also capable of mediating selenoxidation, and that enzymatically generated propargylic and 
allylic selenoxides readily undergo [2,3] sigmatropic rearrangement in the active site of the enzyme (40). 
Based on this precedent, we will examine compound xm as an initial test for DBM-mediated potential 
[2,3] sigmatropic rearrangements. As shown in the scheme, compound xm should readily undergo [2,3] 
sigmatropic rearrangement upon selenoxidation, to generate a highly reactive species, allenic selenic ester 
(XIIIa), capable of leading to enzyme inactivation. We anticipate that compounds such as xm should be 
good DBM substrates based on the following two reasons: a) Our own work has established that cognates 
of both P AESe and P AES which contain substituents in the alkyl side chain are still excellent substrates for 
DBM; b) Substitution of an acetylenic group at the benzylic position of the "classical" DBM substrate, 
tyramine, does not abolish the substrate activity (S-enantiomer of compound XIllb is a substrate for 
DBM); in fact, it increases the affinity for binding significantly (41). Compound xm will be synthesized 
by treating the phenyl methanesulfonate of the corresponding N-protectcd amino alcohol with sodium 
phenyl selenate. If we encounter problems due to the competing SN2' addition of phenylselenide to the 
acetylenic moiety in the above synthesis, we will use trimethylsilyl blocked sodium acetilide instead of 
sodium acetilide and this group will be removed at the last step by treating with F-. TheN-protected 
amino alcohol, 2-hydroxy-4-acetamido-1-butyne will be prepared by treating the 3-acetamido propanal 
with sodium acetylide in liquid ammonia according to the procedure by Billimoria and Maclagan ( 42). 
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D. PjcoHnic Acid Based Inhjbjtors for DBM: 
Xllla 
5-Alkyl picolinic acids are long-mown to be potent inhibitors for DBM, and the most potent of all, 
fusaric acid [5-butyl picolinic acid, (XIV)], is known to exhibit potent antihypertensive activity (43) 
Although a complete characterization of inhibition of DBM by picolinic acid has never been reported, the 
existing evidence suggests. that the inhibition is due to the .chelation of active site Cu (43). We will 
synthesize and examine a series of derivatives of 5-substituted picolinic acid that are designed tp be better 
Cu(m chelators than fusaric acid itself. N-oxides and ketoximes are better ligands for copper than 
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pyridine nitrogen or carboxylic acids, respectively ( 44 ). We therefore will examine compounds XV and 
XVI as potential inhibitors for DBM. The results obtained with these compounds may be valuable in 
designing more potent and specific inhibitors for DBM, and they may also help reveal structural 
infonnation about the DBM active site Cu. These compounds will be synthesized from commercially 
available substituted picolinic acid derivatives by standard synthetic methods. For example, the 
hydroxylamine derivative XVI will be synthesized by simple nucleophilic displacement reactions of easily 
accessible ester derivatives of substituted picolinic acids with hydroxyl amine. The N-oxide XV will be 












Recently, Kruse et al have demonstrated that 1-(4-hydroxyphenyl)imidazole-2-thiol (XVII) is an 
extremely potent competitive inhibitor for DBM ( 45). They suggested that the potent inhibition is due to 
the ability of xvn to act as a multisubstrate mimic of the binding of oxygen and phenylethylamine to the 
reduced enzyme. Based on the above precedent, compounds s.uch as xvm-XX may be potent inhibitors 
for DBM. Due to the flexibility of the side chain and the presence of a free terminal amino group in these 
compounds, it is possible that these compounds may be even better reversible inhibitorS for DBM than 
xvn. In addition, compounds XXI and xxn are designed to test whether the positioning of a strong 
copper ligand such as hydroxylamine or thiol in the hydroxylation site will lead to the enzyme inactivation 
by tightly interacting with the active site copper(s) of DBM. While, compounds xvm and XIX are 
commercially available, N-hydroxy N-phenylethylenediamine will be synthesized by reacting 0-alkoxy 
aniline derivatives with N-protected 2-bromoethylamine and then, acid deblocking of both protecting 
groups. Compound xxn will be synthesized by the treatment of 2-chloro-2-phenylethylamine with 
N a2S03 followed by acid hydrolysis ( 46). 
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PrototYPe Inhibitors Tameted at Iyrosine Hydroxylase 
Our basic approach to date has obviously been to design and evaluate novel compounds targeted at 
DBM. As detailed in BACKGROUND, our rationale for this approach is recognition that DBM is 
conveniently sequestered together with its b-561 ascorbate recycling system within catecholamine vesicles, 
that our compounds are effectively transported to the target DBM via presynaptic uptake and vesiculation, 
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During the next project period we wish to carry out a very limited pilot evaluation of one class of 
compounds targeted at the enzyme tyrosine hydroxylase (TH), the monooxygenase which catalyzes 
hydroxylation of Tyr to dihydroxyphenylalanine (DOPA), thus sitting two steps ahead of DBM in the 
pathway leading from the essential amino acid, Phe, to the neurotransmitter, NE. Ever since the early 
literature on catecholamine biosynthesis, the TH -catalyzed reaction has been regarded as the putative rate 
limiting step (7), although, as pointed out later (8), there may be a shift toward rate determining DA 
hydroxylation under certain metabolic conditions. For our purposes, we are particularly interested in 
contrasting the behavior of a potent TH inhi~itor with those of our DBH-targeted compounds. This would 
provide reference data by which to evaluate the relative advantages of targeting two different points along 
the catecholamine pathway and would provide some indication of the importance of the sequestering and 
uptake accessibility of DBM in terms of rationale drug design. Also, if TH; is indeed the rate limiting step, 
then inhibiting 'IH may well have a much more drastic effect on NE levels than would inhibition o{ DBM; 
thus we may obtain insight into the consequences of "DBM-targeted modulation" vs more drastic ''Til-
targeted cutoff' on NE production. 
One fmds statements in the literature and in textbooks with an almost anecdotal quality that 1H 
inhibition is not a fruitful approach to antihypertensive agents. [See, for example in Goodman and 
Gilman, 6thEd., page 72: "Unfortunately inhibition of this enzyme is not of therapeutic benefit. ... " and 
references cited]. After perusal of the literature we contend that a careful in vitro study directly 
demonstrating that a particular compound is a potent TH inhibitor, and characterizing its effect on NE 
production is badly needed. The results of such a study, when combined with the reports of others on the 
regulation of TH and its pharmacological consequences, will be very valuable in evaluating the validity of 
conclusions regarding TH-targeting. This is our rationale for proposing our limited pilot study. 
In recent work in our laboratory with the enzyme phenylalanine hydroxylase (P AH) we discovered 
that PAH readily carries out oxygenation of 4-pyridylalanine to the corresponding 4-pyridylalanine-N-
Oxide (53). In the course of this work, we synthesized and fully characterized both various 
pyridylalanines and their corresponding N-oxides. We reason there is an excellent chance that TH will 
similarly carry out conversion of 4-hydroxy-3-pyridylalanine (which exists as its pyridone tautomer) to the 
corresponding N-oxide (Both P AH and rn are non-heme-iron monooxygenases). This N-oxidation 
would generate the corresponding pyridone-N-oxide as the product, which is actually a hydroxamic acid 
N-oxide, an excellent ligand for iron! Thus, the product could readily inhibit TH by ligating to the 
essential Fe atom in the active site. We will therefore carry out a limited pilot project to see if this approach 
to TH inhibition works under standard assay conditions. (TII will be isolated in our laboratory from PC-
12 cells, see ref 54). We will carry out in-vitro enzymology, and if this idea works we will carry out 
studies in chromaffm granule ghosts to contrast the effects on NE production with the effects of our DBM 
inhibitors. No SHR work is planned at this stage since the amino acid structure of our inhibitors ensures 
that there will be central effects that we are not prepared to sort out at this stage. 
PBM Mechanism 
Our ongoing work on this project has certainly made contributions to the mechanistic enzymology 
of DBM, a subject of much interest in a riumber of laboratories. Two particular studies will be carried out 
primarily for the infonnation they can provide about the structure and function of DBM. These entail 
demonstrating DBM-catalyzed aromatization of compounds designed to trap reaction transients generated 
by single electron transfer; and active site peptide mapping with one of our suicide inhibitors which is ideal . 
for this purpose. 
We have very recently observed that DBM catalyzes aromatization of.l-(2-aminoethyl)-1,4-
cyclohexadiene (CHDEA) a process which proceeds via the normal DBM reductive monooxygenation 
pathway. We find this observation very exciting, since aromatization of cyclohexadienes represents a well 
established trapping reaction aiagnostic of single electron transfer processes. As set out in our 
publications, our unified mechanism for DBM processing postulates initial single electron transfer from 
substrate; thus, for example, we visualize that heteroatom cation radicals are initially formed with our N,S 
or Se substrates. 
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We will determine the kinetic characteristics ofCHDEA turnover, and unequivocally prove that the 
only product from the CHDEA/DBM reaction is 2-phenylethylamine; to date we have no evidence for any 
oxygenated products being formed. lH-NMR, 2H-NMR and GC-MS analysis of the product from paired 
enzymatic reactions, carried out either in H20 or in 2H20, will demonstrated whether deuterium 
incorporation into the product, 2-phenylethylamine, occurs during CHDEAIDBM turnover. Dideuterated 
CHDEA (CHDEA-d2) will also be prepared and examined as a substrate for DBM. The NMR and Ge-
MS analysis of the product from CHDEA-d2/DBM ~action will reveal whether loss of deuterium at the 
benzylic position of the product occurs. If aromatization of CHDEA during DBM turnover indeed arises 
solely from initial single electron transfer from the cyclohexadiene moiety to the activated copper-oxygen 
specie- and not from a methylene hydroxylation pathway - then no deuterium incorporation or loss will 
be seen in these two experiments, respectively. Thus, lack of deuterium loss (or incorporation) would 
effectively rule out any mechanism involving initial hydroxylation at the exocyclic methylene followed by 
aromatization in DBM/CHDEA reaction, but would be consistent with initial abstraction ofH from a ring 
methylene. Since aromatization of cyclohexadienes represents a well established trapping reaction 
diagnostic of single electron transfer processes, these experiments may provide direct support for the 
ability of the activated copper oxygen species ofDBM to carry out a single electron transfer process. 
Recently, several attempts have been made to map the active site of DBM by using active site 
directed radiolabeled suicide inhibitors. (49). However, results of these experiments have not been 
successful due to the non-specific labeling of a large number of pep tides in the tryptic map. In our view, a 
major problem with these previous studies is that the inhibitors used do not possess a terminal amine 
functionality. Our work with non-amine containing compounds clearly indicates to us that such 
compounds interact "loosely" with the active site ofDBM (51). Therefore, it is possible_that the 
nonspecific labeling of several peptides may be a result of "movement" of the enzyme-activated species 
within the active site of the enzyme during the inactivation process. In our previous studies, we have 
developed several classes of terminal-amine-containing suicide inhibitors for DBM (29). With both P AME 
and PEDA (our olefmic and N-dealkylating classes), we have extensively characterized the mechanism of 
inhibition. We have developed the methodology for, and successfully carried out, of ring tritiated N-
phenylethylenediamine (PEDA) with high specific activity, in our laboratory and shown that a 
stoichiometrically consistent amount of radioactivity is incorporated into the enzyme during the inactivation 
(28). Similar results have been obtained with tritiated P AME. We therefore propose to use tritiated 
PEDA, (we already have ca. 300 mg in hand) to map the active site of DBM Since PEDA is a potent 
suicide inhibitor for DBM and structurally very similar to the "regular" substrate, phenylethylamine, we 
expect that we will not encounter the complications which have plagued previous attempts by others. 
Since the complete amino acid sequence of DBM is now known (52), we will be able to compare our 
results with sequence data for confmnation. 
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F. VERTEBRATE ANIMALS 
All of the animal experiments which are described in this proposal will begin at Mercer 
University School of Pharmacy under the direction of Dr. Herman, who has experience in 
managing animal populations~ At Mercer, we have contracted for the use of a well-equipped 
modem animal care facility which includes caging designed for dog, guinea-pig, rabbit, rat, and 
mouse populations. This facility was especially designed for animal care and has all of the 
pertinent sanitary features, including separate rooms for food storage and preparation, surgical 
appliances, and disposal equipment including an incinerator for sacrificed animals. We have 
contracted for the use of these facilities for the past six years, and are assured that this arrangement 
will continue for the foreseeable future. We will house a population of both SHR and WKY rats · 
(Charles River) at Mercer. We hereby affum that we will conform to the guidelines suggested for . 
the use of experimental animals outlined in "Guiding Principles in the Care and Use of Animals" 
(publ. by the Council of the American Physiological Society), the "Principles for the Use of 
Animals" (OPRR), and the "Guide for the Care and Use of Laboratory Animals" (OPPR) in the 
proposed investigations. 
There are two types of animal experiments proposed here, one involving SHRs and one 
involving normal rats. Test animals - both nonnal (WKY) and SHR (CRL:CD9SD/BR) rats --
will be purchased from a reputable dealer (Charles River), housed in approved caging for a 
maximum of a few weeks, and used for bp measurements as outlined in the body of the proposal. 
Animals will be sacrificed by cervical dislocation, and sacrificed animals ~ be incinerated. 
The proposed experiments involved a relatively small number of animals. We expect to use 
approximately 100 SH rats and 100 normal rats. All rats will be male, 9-13 weeks old, purchased 
in batches of 20 from a national supplier (currently Charles River). We believe that these 
experiments are quite necessary to the goals of this research, and that our studies will benefit the 
health of man, the welfare of human society and the progress of knowledge. This proposal has 
been reviewed and approved by the Animal Welfare Committee (letter attached). 
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G. COLLABORATORS 
We will collaborate with Professor Richard Browner of the School of Chemistry and Biochemistry 
of Georgia Institute of Technology for the purpose of applying the exciting new technique of ICP/MS to 
the detection and quantitation of our selenides and their metabolites in biological samples. Professor 
Browner possesses one of a total of only four such units in use in academic laboratories in North America, 
and his group has pioneered research in sample introduction approaches for ultra micro trace analysis. 
With their instrument, they will be able to measure selenium at levels of 10 nano-molar or better which is 
more than enough sensitivity for our purposes. As explained in the body of the proposal, this technique 
will be of particular value in our PC-12 experiments and in our pharmacodynamic experiment with our 
selenides. 
We will collaborate with two pharmacologists at the School ofPhannacy of the University of. 
Georgia - .Drs Randall Tackett and Diane Hartle. Drs. Tackett and Hartle have already obtained used their 
sophisticated computerized hemodynamic instrumentation to clearly confum the antihypertensive activity 
of P AESe. Phannacological experiments to probe cardiovascular effects of our selenides on isolated blood 
vessels are in progress. They have also initiated similar studies with PEDA. These investigations 
represent the fmallink in the chain of experimentation on which we have embarked - now spanning from 
enzyme to ghosts to cells to isolated vessels to whole animals. In addition, Drs. Tackett and Hartle have 
agreed that due to unique biochemical mechanisms operative with .our compounds, they are highly 
interesting to them as neurochemical probes. We are looking forward to further collaboration along these 
lines in the future. 
Dr. Richard Mailman of the University of North Carolina has initiated a collaboration with us to 
evaluate the effects of our DBH-directed compounds in Brindled Mottled Mutant mice. We anticipate that 
the unique biochemical properties of our compounds will enable us to <.?btain important information about 
the relationship between DBH activity and the development of noradrenergic innervation. This is an 
important frontier research area in neuroscience. 
We will continue our relationship with Professor Leon Goldberg, Chainnan of the Committee on 
Clinical Phannacology at the University of Chicago. SWM and one of the project personnel have visited 
Dr. Goldberg's laboratory, and we have had a number of discussions regarding the cardiovascular 
pharmacology of our compounds in light of our bioassay results. Dr. Goldberg is also very interested in 
the unique properties of our compounds because interfering with DBM may lead to a buildup of DA, a 
molecule known to have vasodilator action, particularly in the renal and mesenteric vasculature. This is an 
area in Professor Goldberg is an acknowledged international authority. While we have now developed 
considerable expertise in carrying out bioassays for cardiovascular activities of our compounds and in 
probing the pharmacological mechanisms operative, Dr. Goldberg has kindly consented to serve both as 
an expert consultant in cardiovascular phannacology, and as a collaborator in further evaluating those 
compounds of interest from his clinical perspective. 
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